Multiple Myeloma in Relapse Recruiting Phase 2 Trials for Melphalan (DB01042)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03030261Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaTreatment